Zentalis Pharmaceuticals announced encouraging Phase 1b trial data showing that combining their investigational drug azenosertib with paclitaxel achieved a 39% overall response rate and a median progression-free survival of 7.3 months in patients with platinum-resistant ovarian cancer. The combination demonstrated manageable safety with low rates of severe side effects, especially at the 250 mg intermittent dose, which showed a 50% response rate and durable responses. These results suggest azenosertib could enhance treatment options for ovarian cancer, supporting further clinical development and broader testing in other cancers where taxanes are used. Data were presented at the 2026 ASCO meeting, with additional combination data forthcoming.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
